MDT

95.27

-1.1%↓

VEEV

286.7

-0.82%↓

A

139.27

-0.3%↓

HQY

93.51

-1.82%↓

TLRY

1.69

+3.68%↑

MDT

95.27

-1.1%↓

VEEV

286.7

-0.82%↓

A

139.27

-0.3%↓

HQY

93.51

-1.82%↓

TLRY

1.69

+3.68%↑

MDT

95.27

-1.1%↓

VEEV

286.7

-0.82%↓

A

139.27

-0.3%↓

HQY

93.51

-1.82%↓

TLRY

1.69

+3.68%↑

MDT

95.27

-1.1%↓

VEEV

286.7

-0.82%↓

A

139.27

-0.3%↓

HQY

93.51

-1.82%↓

TLRY

1.69

+3.68%↑

MDT

95.27

-1.1%↓

VEEV

286.7

-0.82%↓

A

139.27

-0.3%↓

HQY

93.51

-1.82%↓

TLRY

1.69

+3.68%↑

Search

MannKind Corp

Atvērts

SektorsVeselības aprūpe

5.2 1.76

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.05

Max

5.21

Galvenie mērījumi

By Trading Economics

Ienākumi

-12M

668K

Pārdošana

-1.8M

77M

P/E

Sektora vidējais

46.364

36.442

Peļņas marža

0.873

Darbinieki

403

EBITDA

-17M

9.7M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+107.25% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

373M

1.6B

Iepriekšējā atvēršanas cena

3.44

Iepriekšējā slēgšanas cena

5.2

Ziņu noskaņojums

By Acuity

29%

71%

81 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. okt. 22:33 UTC

Peļņas

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

2025. g. 14. okt. 22:21 UTC

Galvenie tirgus virzītāji

Dentsply Sirona Shares Rise After SEC Probe Ends

2025. g. 14. okt. 19:27 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

2025. g. 14. okt. 17:56 UTC

Galvenie tirgus virzītāji

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

2025. g. 14. okt. 23:38 UTC

Tirgus saruna

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

2025. g. 14. okt. 22:12 UTC

Tirgus saruna
Peļņas

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

2025. g. 14. okt. 21:40 UTC

Peļņas

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

2025. g. 14. okt. 21:39 UTC

Peļņas

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

2025. g. 14. okt. 21:38 UTC

Peļņas

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

2025. g. 14. okt. 21:06 UTC

Peļņas

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

2025. g. 14. okt. 20:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 14. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 14. okt. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 14. okt. 20:50 UTC

Tirgus saruna
Peļņas

Health Care Roundup: Market Talk

2025. g. 14. okt. 20:13 UTC

Peļņas

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

2025. g. 14. okt. 20:01 UTC

Peļņas

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

2025. g. 14. okt. 19:21 UTC

Tirgus saruna
Peļņas

Citigroup's Higher Outlook Leaves Questions -- Market Talk

2025. g. 14. okt. 19:12 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

2025. g. 14. okt. 19:08 UTC

Tirgus saruna

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

2025. g. 14. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

2025. g. 14. okt. 18:59 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

2025. g. 14. okt. 18:58 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

2025. g. 14. okt. 18:58 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

2025. g. 14. okt. 18:56 UTC

Iegādes, apvienošanās, pārņemšana

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

2025. g. 14. okt. 18:46 UTC

Peļņas

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

2025. g. 14. okt. 18:04 UTC

Peļņas

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

2025. g. 14. okt. 18:01 UTC

Tirgus saruna

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

2025. g. 14. okt. 17:54 UTC

Peļņas

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

2025. g. 14. okt. 17:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. okt. 17:50 UTC

Tirgus saruna

Lower Dollar Provides Some Strength in Grains -- Market Talk

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

107.25% augšup

Prognoze 12 mēnešiem

Vidējais 10.57 USD  107.25%

Augstākais 15 USD

Zemākais 8 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.079 / 4.323Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

81 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat